AFN inhibited TrxR activity, upregulated Nrf2 signaling, and downregulated the levels of inflammatory cytokines, with a concurrent improvement of the clinical features in the RR-EAE mouse model of MS. Here, NFE2L2 is linked to myeloid sarcoma.